Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes

Celestino Sardu, Michelangela Barbieri, Matteo Santamaria, Valerio Giordano, Cosimo Sacra, Pasquale Paolisso, Alessandro Spirito, Raffaele Marfella, Giuseppe Paolisso, Maria Rosaria Rizzo, Celestino Sardu, Michelangela Barbieri, Matteo Santamaria, Valerio Giordano, Cosimo Sacra, Pasquale Paolisso, Alessandro Spirito, Raffaele Marfella, Giuseppe Paolisso, Maria Rosaria Rizzo

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart patients treated by cardiac resynchronization therapy with a defibrillator (CRT-d).

Methods: One hundred and ninety-five T2DM patients received a CRT-d treatment. Randomly the study population received a CRT-d via multipolar left ventricle (LV) lead pacing (n 99, multipolar group), vs a CRT-d via bipolar LV pacing (n 96, bipolar group). These patients were followed by clinical, and instrumental assessment, and telemetric device control at follow up. In this study we evaluated, in a population of failing heart T2DM patients, cardiac deaths, all cause deaths, arrhythmic events, CRT-d responders rate, hospitalizations for HF worsening, phrenic nerve stimulation (PNS), and LV catheter dislodgment events (and re-intervention for LV catheter re-positioning), comparing multipolar CRT-d vs bipolar CRT-d group of patients at follow up.

Results: At follow up there was a statistical significant difference about atrial arrhythmic events [7 (7%) vs 16 (16.7%), p value 0.019], hospitalizations for HF worsening [15 (15.2% vs 24 (25%), p value 0.046], LV catheter dislodgments [1 (1%) vs 9 (9.4%), p value 0018], PNS [5 (5%) vs 18 (18.7%), p value 0.007], and LV re-positioning [1 (1%) vs 9 (9.4%), p value 0.018], comparing multipolar CRT-d vs bipolar CRT-d group of patients. Multipolar pacing was an independent predictor of all these events.

Conclusions: CRT-d pacing via multipolar LV lead vs bipolar LV lead may reduce arrhythmic burden, hospitalization rate, PNS, LV catheters dislodgments, and re-interventions in T2DM failing heart patients. Clinical trial number NCT03095196.

Figures

Fig. 1
Fig. 1
In this figure study flow chart representation. The study was conducted by the following phases: screening phase, inclusion phase, intervention phase, follow up phase. In the screening phase, 213 consecutive T2DM patients [with chronic heart failure lasting for at least 3 months, New York Heart Association (NYHA) functional class II or III, left bundle brunch block, severe left ventricle ejection fraction reduction (LVEF 

Fig. 2

In this figure the representation…

Fig. 2

In this figure the representation of cumulative survival events free curves for study…

Fig. 2
In this figure the representation of cumulative survival events free curves for study endpoints, by Cox regression analysis curves. The figure is structured in seven parts, as a–f, Fig. 3. In green color the bipolar group, in blue color the multipolar group for each figure part. The symbol asterisk was marking a statistical significant event, as indicated by a p value <0.05. In the part a of the figure, the curve representation of Phrenic Nerve stimulation events as “cumulative risk for Phrenic Nerve stimulation” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part b of the figure, the curve representation of catheter dislocation events as “cumulative risk for catheter dislodgement events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part c of the figure, the curve representation of re-interventions for left ventricle lead re-positioning after dislodgment as “cumulative risk for re-interventions for left ventricle catheter re-positioning” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part d of the figure, the curve representation of hospital admission events as “cumulative risk for hospital admissions events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part e of the figure, the curve representation of atrial fibrillation events as “cumulative risk for atrial fibrillation events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part f of the curve, the representation of all cause of deaths events as “cumulative risk for all cause of deaths events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group

Fig. 3

In this figure the representation…

Fig. 3

In this figure the representation of cumulative survival events free curves for study…

Fig. 3
In this figure the representation of cumulative survival events free curves for study endpoints, by Cox regression analysis curves. In the part of the curve, the representation of cardiac deaths events as “cumulative risk for cardiac deaths events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group
Fig. 2
Fig. 2
In this figure the representation of cumulative survival events free curves for study endpoints, by Cox regression analysis curves. The figure is structured in seven parts, as a–f, Fig. 3. In green color the bipolar group, in blue color the multipolar group for each figure part. The symbol asterisk was marking a statistical significant event, as indicated by a p value <0.05. In the part a of the figure, the curve representation of Phrenic Nerve stimulation events as “cumulative risk for Phrenic Nerve stimulation” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part b of the figure, the curve representation of catheter dislocation events as “cumulative risk for catheter dislodgement events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part c of the figure, the curve representation of re-interventions for left ventricle lead re-positioning after dislodgment as “cumulative risk for re-interventions for left ventricle catheter re-positioning” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part d of the figure, the curve representation of hospital admission events as “cumulative risk for hospital admissions events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part e of the figure, the curve representation of atrial fibrillation events as “cumulative risk for atrial fibrillation events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group. In the part f of the curve, the representation of all cause of deaths events as “cumulative risk for all cause of deaths events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group
Fig. 3
Fig. 3
In this figure the representation of cumulative survival events free curves for study endpoints, by Cox regression analysis curves. In the part of the curve, the representation of cardiac deaths events as “cumulative risk for cardiac deaths events” (on y axis) during 360 days follow up (on x axis) comparing multipolar vs bipolar group

References

    1. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251–258. doi: 10.1001/jamainternmed.2013.12956.
    1. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000;101:2271–2276. doi: 10.1161/01.CIR.101.19.2271.
    1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035–2038. doi: 10.1001/jama.1979.03290450033020.
    1. Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svenson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20985 patients with type 1 diabetes: an observational study. Lancet. 2011;378:140–146. doi: 10.1016/S0140-6736(11)60471-6.
    1. Moss AJ, Jackson Hall W, Cannom DS, Klein H, Brown MW, James WS, Daubert P, Mark Estes NA, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, for the MADIT-CRT Trial Investigators* Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338. doi: 10.1056/NEJMoa0906431.
    1. Fantoni C, Regoli F, Ghanem A, Raffa S, Klersy C, Sorgente A, Faletra F, Baravelli M, Inglese L, Salerno-Uriarte JA, Klein HU, Moccetti T, Auricchio A. Long-termoutcomein diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail. 2008;10(3):298–307. doi: 10.1016/j.ejheart.2008.01.006.
    1. George J, Barsheshet A, Moss AJ, Martin D, Ouellet G, McNitt S, Goldenberg I. Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy. Ann Non invasive Electrocardiol. 2012;2012(17):14–21. doi: 10.1111/j.1542-474X.2011.00476.x.
    1. Hoppe UC, Freemantle N, Cleland JGF, Marijianowski M, Erdmann E. Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure. Diabetes Care. 2007;30:722–724. doi: 10.2337/dc06-2035.
    1. Mangiavacchi M, Gasparini M, Genovese S, Pini D, Klersy C, Bragato R, Andreuzzi B, Municinò A, Regoli F, Galimberti P, Ceriotti C, Gronda E. Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2008;31:1425–1432. doi: 10.1111/j.1540-8159.2008.01206.x.
    1. Ruwald AC, Schuger C, Moss AJ, Kutyifa V, Olshansky B, Greenberg H, Cannom DS, Estes NA, Ruwald MH, Huang DT, Klein H, McNitt S, Beck CA, Goldstein R, Brown MW, Kautzner J, Shoda M, Wilber D, Zareba W, Daubert JP. Mortalityreduction in relation to implantable cardioverter defibrillator programming in the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) Circ: Arrhythm Electrophysiol. 2014;7(5):785–792.
    1. Sardu C, Marfella R, Santulli G. Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people. J Cardiovasc Transl Res. 2014;7(3):362–368. doi: 10.1007/s12265-014-9545-9.
    1. Echouffo-Tcheugui JB, Masoudi FA, Bao H, Spatz ES, Fonarow GC. Diabetes mellitus and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure. Circ Arrhythm Electrophysiol. 2016;9(8):e004132. doi: 10.1161/CIRCEP.116.004132.
    1. Boriani G, Connors S, Kalarus Z, Lemke B, Mullens W, Asensi JO, Raatikainen P, Gazzola C, Farazi TG, Leclercq C. Cardiac resynchronization therapy with a quadripolar electrode lead decreases complications at 6 months results of the MORE-CRT randomized trial. JACC: Clin Electrophysiol. 2016;2:2.
    1. Osnat G, Eyal N, Shemy C, David L, Bar-Lev D, Nechemya T, Eldar M, Glikson M. Programmable multiple pacing configurations help to overcome high left ventricular pacing thresholds and avoid phrenic nerve stimulation. Pacing Clin Electrophysiol. 2005;28(12):1255–1259. doi: 10.1111/j.1540-8159.2005.00265.x.
    1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA, 3rd, Ferguson TB, Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD. American College of Cardiology Foundation.; American Heart Association Task Force on Practice Guidelines.; HeartRhythm Society. 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol. 2013;61(2):e1–e6.
    1. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, ESC Committee for Practice Guidelines (CPG) Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers. Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bänsch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) Eur Heart J. 2013;34:2281–2329. doi: 10.1093/eurheartj/eht150.
    1. Maisel WH. Physician management of pacemaker and implantable cardioverter defibrillator advisories. Pacing Clin Electrophysiol. 2004;27:437–442. doi: 10.1111/j.1540-8159.2004.00460.x.
    1. Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, Christensen J, Stadler RW, Lau CP. Intrathoracic impedance monitoring in patients with heart failure correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841–848. doi: 10.1161/CIRCULATIONAHA.104.492207.
    1. Prochazka A, Korpas D. Monitoring biventricular pacing parameters dependingon the left ventricle lead configuration. Exp Clin Cardiol. 2013;18(2):85–88.
    1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014 ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2014;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.021.
    1. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) Eur Heart J. 2015;36(41):2793–2867. doi: 10.1093/eurheartj/ehv316.
    1. Forleo GB, Della Rocca DG, Papavasileiou LP, Molfetta AD, Santini L, Romeo F. Left ventricular pacing with a new quadripolartransvenous lead for CRT: earlyresults of a prospective comparison with conventional implant outcomes. Heart Rhythm. 2011;8:31–37. doi: 10.1016/j.hrthm.2010.09.076.
    1. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176–182. doi: 10.1054/jcaf.2001.25652.
    1. Steiner H, Geist M, Goldenberg I, Suleiman M, Glikson M, Tenenbaum A, Swissa M, Fisman EZ, Golovchiner G, Strasberg B, Barsheshet A, Israeli Working Group of Pacing and EP Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry. Cardiovasc Diabetol. 2016;15(1):160. doi: 10.1186/s12933-016-0478-2.
    1. Biffi M, Moschini C, Bertini M, Saporito D, Ziacchi M, Diemberger I, Valzania C, Domenichini G, Cervi E, Martignani C, Sangiorgi D, Branzi A, Boriani G. Phrenicstimulation a challenge for cardiac resynchronization therapy. Circ: Arrhythm Electrophysiol. 2009;2(4):402–410.
    1. Seifert M, Schau T, Moeller V, Neuss M, Meyhoefer J, Butter C. Influence of pacing configurations, body mass index, and position of coronary sinus lead on frequency of phrenic nerve stimulation and pacing thresholds under cardiac resynchronization therapy. Europace. 2010;12(7):961–967. doi: 10.1093/europace/euq119.
    1. Hallier MS, Rinaldi CA. First prospective, multi-centre clinical experience with a novel left ventricular quadripolarlead. Europace. 2012;14:365. doi: 10.1093/europace/eur322.
    1. Champagne J, Healey JS, Krahn AD, Philippon F, Gurevitz O, Swearingen A, Glikson M. The effect of electronic repositioning on left ventricular pacing and phrenic nerve stimulation. Europace. 2011;13(3):409–415. doi: 10.1093/europace/euq499.
    1. Behar JM, Bostock J, Zhu Li AP, Chin HM, Jubb S, Lent E, Gamble J, Foley PW, Betts TR, Rinaldi CA, Herring N. Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mortality and elimination of phrenic nerve stimulation: long-term follow-up from a multicenter registry. J Cardiovasc Electrophysiol. 2015;26(5):540–546. doi: 10.1111/jce.12625.
    1. Jones MA, Khiani R, Foley P, Webster D, Qureshi N, Wong KC, Rajappan K, Bashir Y, Betts TR. Inter- and intravein differences in cardiac output with cardiac resynchronization pacing using a multipolar LV pacing lead. Pacing Clin Electrophysiol. 2015;38(2):267–274. doi: 10.1111/pace.12531.
    1. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Free-mantle N, Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation. 2006;114:18–25. doi: 10.1161/CIRCULATIONAHA.106.614560.
    1. Lellouche N, De Diego C, Vaseghi M, Buch E, Cesario DA, Mahajan A, Wiener I, Fonarow GC, Boyle NG, Shivkumar K. Cardiac resynchronization therapy response is associated with shorter duration of atrial fibrillation. Pacing Clin Electrophysiol. 2007;30(11):1363–1368. doi: 10.1111/j.1540-8159.2007.00872.x.
    1. Mahajan R, Lau DH, Sanders P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc Med. 2015;25(2):119–126. doi: 10.1016/j.tcm.2014.09.005.
    1. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, Finnie JW, Samuel CS, Royce SG, Twomey DJ, Thanigaimani S, Kalman JM, Sanders P. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol. 2015;66(1):1–11. doi: 10.1016/j.jacc.2015.04.058.
    1. Calò L, Martino DeRuvo E, Minati M, Fratini S, Rebecchi M, et al. Acute echocardiographic optimization of multiple stimulation configurations of cardiac resynchronization therapy through quadripolar left ventricular pacing: a tailored approach. Am Heart J. 2014;167:547–554. doi: 10.1016/j.ahj.2013.12.028.
    1. Szepietowska B, Polonsky B, Sherazi S, Biton Y, Kutyifa V, McNitt S, Aktas M, Moss AJ, Zareba W. Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. Cardiovasc Diabetol. 2016;15:93. doi: 10.1186/s12933-016-0401-x.
    1. Cabrera BF, Alzueta RJ, Olaguede RJ, Fernandez-Lozano I, Garcıa Guerrero JJ, de la Concha JF, et al. Improvement in hemodynamic better programmability with quartet than bi- and tripolar equivalents. Pacing Clin Electrophysiol. 2013;36:963–969. doi: 10.1111/pace.12172.
    1. Cai C, Hua W, Ding LG, Wang J, Chen KP, Yang XW, Liu ZM, Zhang S. Association of body mass index with cardiac reverse remodeling and long-term outcome in advanced heart failure patients with cardiac resynchronization therapy. Circ J. 2014;78(12):2899–2907. doi: 10.1253/circj.CJ-14-0812.
    1. Axelsen LN, Calloe K, Braunstein TH, Riemann M, Hofgaard JP, Liang B, Jensen CF, Olsen KB, Bartels ED, Baandrup U, Jespersen T, Nielsen LB, Holstein-Rathlou NH, Nielsen MS. Diet-induced pre-diabetes slows cardiac conductance and promotes arrhythmogenesis. Cardiovasc Diabetol. 2015;14:87. doi: 10.1186/s12933-015-0246-8.
    1. Sardu C, Santamaria M, Rizzo MR, Barbieri M, di Marino M, Paolisso G, Santulli G, Marfella R. Telemonitoring in heart failure patients treated by cardiac resynchronization therapy with defibrillator (CRT-D): the TELECART Study. Int J ClinPract. 2016;70(7):569–576.
    1. Sardu C, Barbieri M, Rizzo MR, Paolisso P, Paolisso G, Marfella R. Cardiac resynchronization therapy outcomes in type 2 diabetic patients: role of MicroRNA changes. J Diabetes Res. 2016:7292564.
    1. Sardu C, Marfella R, Santulli G, Paolisso G. Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics. 2014;8:1159–1168. doi: 10.2217/pgs.14.76.
    1. Umar F, Taylor RJ, Stegemann B, Marshall H, Flannigan S, Lencioni M, De Bono J, Griffith M, Leyva F. Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study. Europace. 2016;18(8):1227–1234. doi: 10.1093/europace/euv396.
    1. Shetty AK, Sohal M, Chen Z, Ginks MR, Bostock J, Amraoui S, Ryu K, Rosenberg SP, Niederer SA, Gill J, Carr-White G, Razavi R, Rinaldi CA. A comparison of left ventricular endocardial, multisite, and multipolar epicardial cardiac resynchronization: an acute haemodynamic and electroanatomical study. Europace. 2014;16(6):873–879. doi: 10.1093/europace/eut420.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere